Last reviewed · How we verify
NCT04277832: TUPAST
Evaluating of New Screening Tool for Arthritis* in Psoriasis
trial testing Questionary in Psoriasis in 200 participants. Completed in 13 January 2021.
13 January 2021
Quick facts
| Lead sponsor | Bezmialem Vakif University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 21 February 2020 |
| Primary completion | 13 January 2021 |
| Estimated completion | 13 January 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Questionary
Conditions studied
- Psoriasis — all drugs for Psoriasis →
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Sponsor
Bezmialem Vakif University
Who can join
Adults 18 to 75, any sex, with Psoriasis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates a new screening tool for arthritis in psoriasis and compares its reliability with well-known screening tool (TOPAS 2).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04277832
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionary
Trials testing the same drug.
- NCT06666543 — Becoming HIV-Exposed, Uninfected Children Born to HIV-Positive Mothers Followed at Bichat Claude Bernard Hospital · completed
- NCT05850442 — The Relationship Between Fibromyalgia Syndrome Parameters With Disease-Pain Severity and the Quality Of Life · completed
- NCT04768621 — Health Consequences of Wintering in the French Southern and Antarctic Territories · NA · completed
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
Other Bezmialem Vakif University trials
Trials by the same sponsor.
- NCT07369297 — PULP SENSIBILITY AND MASSETER INHIBITORY REFLEX IN DIABETIC POLYNEUROPATHY · not yet recruiting
- NCT07433595 — Association Between Child and Parental Stress and Bruxism in Children Aged 8-11 Years · not yet recruiting
- NCT07443111 — Comparison of Virtual Reality-Based and Routine Preoperative Education on Surgical Anxiety and Salivary Cortisol · NA · not yet recruiting
- NCT07421349 — Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy P · not yet recruiting
- NCT07414615 — Aerobic Training in Lower Extremity Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04277832 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bezmialem Vakif University
- Last refreshed: 14 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04277832.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing